New_Phesi_logo_May23

Global Data Analysis of Clinical Development:
Top Five Studied Diseases in 2025

Phesi’s annual Top Five Studied Diseases report tracks the world’s most studied diseases using Phesi’s award-winning, AI-powered Trial Accelerator™ which leverages contextualized real-world data from more than 300 million patients. Now in its fifth year, the report is based on 65,892 recruiting clinical trials from across the world and in addition to highlighting the most studied diseases, it examines changes in Phase II trial attrition rates and monitors the top five countries hosting clinical trial sites.

Front page Top 5 studied diseases

Implications for Clinical Development

Discover the key findings of the report and how to gain greater precision, insight and certainty in clinical development:

◽ Breast cancer is most studied disease area for the fifth year running

◽ United States leads trial activity across top five indications

◽ One in four trials are terminated in Phase II